Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:ADXS NASDAQ:GRCE NASDAQ:RVPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.19-9.2%$1.22$0.88▼$5.48$34.06M0.56122,014 shs77,026 shsADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/AGRCEGrace Therapeutics$2.20-4.3%$2.88$1.79▼$5.18$35.59M0.37262,082 shs406,734 shsRVPHReviva Pharmaceuticals$0.68-10.0%$0.69$0.26▼$17.20$8.97M0.56529,239 shs90,340 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+1.55%-9.03%+24.76%+3.15%-21.56%ADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,701.64%GRCEGrace Therapeutics-0.43%-4.37%-1.29%-45.24%-19.30%RVPHReviva Pharmaceuticals+6.67%+24.14%-4.45%-69.23%-95.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.19-9.2%$1.22$0.88▼$5.48$34.06M0.56122,014 shs77,026 shsADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/AGRCEGrace Therapeutics$2.20-4.3%$2.88$1.79▼$5.18$35.59M0.37262,082 shs406,734 shsRVPHReviva Pharmaceuticals$0.68-10.0%$0.69$0.26▼$17.20$8.97M0.56529,239 shs90,340 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+1.55%-9.03%+24.76%+3.15%-21.56%ADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,701.64%GRCEGrace Therapeutics-0.43%-4.37%-1.29%-45.24%-19.30%RVPHReviva Pharmaceuticals+6.67%+24.14%-4.45%-69.23%-95.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 1.00SellN/AN/AADXSAyala Pharmaceuticals 0.00N/AN/AN/AGRCEGrace Therapeutics 2.00Hold$6.00172.73% UpsideRVPHReviva Pharmaceuticals 2.50Moderate Buy$66.679,648.01% UpsideCurrent Analyst Ratings BreakdownLatest RVPH, ADXS, GRCE, and ABVC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026GRCEGrace Therapeutics Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/24/2026GRCEGrace Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.004/21/2026GRCEGrace Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026RVPHReviva Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026RVPHReviva Pharmaceuticals Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K60.67N/AN/A$0.52 per share2.29ADXSAyala Pharmaceuticals$3.24M11.05N/AN/A($2.06) per share-0.29GRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$1.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$7.91M-$0.40N/AN/AN/AN/A-62.46%-39.99%8/18/2026 (Estimated)ADXSAyala Pharmaceuticals-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/AGRCEGrace Therapeutics-$9.57M-$0.40N/AN/AN/AN/A-15.58%-14.51%6/22/2026 (Estimated)RVPHReviva Pharmaceuticals-$19.86M-$4.06N/AN/AN/AN/A-391.58%-119.08%8/13/2026 (Estimated)Latest RVPH, ADXS, GRCE, and ABVC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/22/2026Q4 2026GRCEGrace Therapeutics-$0.24N/AN/AN/A$0.90 millionN/A5/18/2026Q1 2026ABVCABVC BioPharmaN/A-$0.06N/A-$0.06N/AN/A5/14/2026Q1 2026RVPHReviva Pharmaceuticals-$0.3550-$0.46-$0.1050-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/AADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.120.12ADXSAyala PharmaceuticalsN/AN/AN/AGRCEGrace TherapeuticsN/A14.9614.96RVPHReviva PharmaceuticalsN/A2.082.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%ADXSAyala Pharmaceuticals7.18%GRCEGrace Therapeutics6.08%RVPHReviva Pharmaceuticals63.18%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma19.00%ADXSAyala Pharmaceuticals0.63%GRCEGrace Therapeutics11.10%RVPHReviva Pharmaceuticals8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3026.00 million21.06 millionNot OptionableADXSAyala Pharmaceuticals2059.31 million42.36 millionNot OptionableGRCEGrace TherapeuticsN/A15.47 million13.76 millionN/ARVPHReviva Pharmaceuticals513.11 million11.67 millionOptionableRVPH, ADXS, GRCE, and ABVC HeadlinesRecent News About These CompaniesReviva Pharmaceuticals (NASDAQ:RVPH) Rating Lowered to "Sell" at Wall Street ZenJune 6, 2026 | americanbankingnews.comReviva Pharmaceuticals (NASDAQ:RVPH) and Gain Therapeutics (NASDAQ:GANX) Financial ReviewJune 1, 2026 | americanbankingnews.comReviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company ShowcaseMay 18, 2026 | finance.yahoo.comReviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company ShowcaseMay 18, 2026 | globenewswire.comOTC Listing Leaves Reviva Pharmaceuticals Shares Vulnerable to Thin Trading and Volatile Price SwingsMay 15, 2026 | tipranks.comReviva Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 13, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK)April 21, 2026 | theglobeandmail.comMaxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress PlansApril 20, 2026 | insidermonkey.comReviva Pharmaceuticals: Reviva Announces Letter to ShareholdersApril 15, 2026 | finanznachrichten.deReviva Pharmaceuticals Holdings, Inc. Updates Shareholders on Strategic Direction and Brilaroxazine DevelopmentApril 15, 2026 | quiverquant.comQReviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00April 9, 2026 | msn.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy†from AnalystsApril 6, 2026 | defenseworld.netDRVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2April 1, 2026 | msn.comReviva Reports Full Year 2025 Financial Results and Recent Business HighlightsMarch 30, 2026 | globenewswire.comReviva Pharmaceuticals Announces One-for-Twenty Reverse Stock SplitMarch 26, 2026 | theglobeandmail.comAnalysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock SplitMarch 25, 2026 | insidermonkey.comTop 10 Stocks Under $5 That Could TripleMarch 24, 2026 | msn.comReviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public OfferingMarch 23, 2026 | finance.yahoo.comReviva Pharmaceuticals Announces $10 Million Equity OfferingMarch 19, 2026 | tipranks.comWhat's Behind The Drop In Reviva Pharmaceuticals Stock?March 19, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVPH, ADXS, GRCE, and ABVC Company DescriptionsABVC BioPharma NASDAQ:ABVC$1.19 -0.12 (-9.16%) Closing price 04:00 PM EasternExtended Trading$1.24 +0.05 (+4.54%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Ayala Pharmaceuticals NASDAQ:ADXS$0.60 0.00 (0.00%) As of 06/11/2026Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Grace Therapeutics NASDAQ:GRCE$2.20 -0.10 (-4.35%) Closing price 04:00 PM EasternExtended Trading$2.25 +0.05 (+2.27%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Reviva Pharmaceuticals NASDAQ:RVPH$0.68 -0.08 (-10.01%) As of 03:59 PM EasternReviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
